Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01GR44F28E3ERPTX6QS5G7D4J2> ?p ?o. }
Showing items 1 to 18 of
18
with 100 items per page.
- 01GR44F28E3ERPTX6QS5G7D4J2 classification D1.
- 01GR44F28E3ERPTX6QS5G7D4J2 promoter F4836E84-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GR44F28E3ERPTX6QS5G7D4J2 promoter F77C2766-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GR44F28E3ERPTX6QS5G7D4J2 date "2023".
- 01GR44F28E3ERPTX6QS5G7D4J2 language "eng".
- 01GR44F28E3ERPTX6QS5G7D4J2 type dissertation.
- 01GR44F28E3ERPTX6QS5G7D4J2 hasPart urn:uuid:8cf1a7cf-4e9f-491a-9ba8-63dcd4b9a250.
- 01GR44F28E3ERPTX6QS5G7D4J2 subject "Medicine and Health Sciences".
- 01GR44F28E3ERPTX6QS5G7D4J2 abstract "RNA therapeutics have the tremendous potential to modulate the expression of virtually any human gene, which offers a broad spectrum of biomedical applications. Unfortunately, the promising therapeutic potential of RNA is restricted by multiple extra- and intracellular barriers, hampering the delivery of the RNA cargo in the cytosol of target cells. Certain small molecules, i.e. cationic amphiphilic drugs (CADs), have been reported to enhance intracellular RNA delivery. In this dissertation, the major goal was to evaluate a co-delivery strategy of clinically available CADs, combined with RNA therapeutics in a single lipid-based nanoparticle system. We first developed cationic vesicles, termed CADosomes, using simple conventional mixing methods to enable mRNA complexation and functional delivery in the corneal epithelial cells of rabbit eyes. Next, state-of-the-art microfluidic mixing technology was implemented to integrate selected CAD molecules in a clinically approved lipid nanoparticle (LNP) formulation for RNA delivery towards the lungs. Finally, a bottom-up approach was implemented to explore the design space of such CAD-LNP combinations and to evaluate the role of each component in more detail for in vitro RNA transfection. Altogether, the data in this work expand our knowledge on LNP-mediated RNA delivery in cells and provide opportunities for the rational development of drug combination therapies.".
- 01GR44F28E3ERPTX6QS5G7D4J2 author E3D8F1FC-FF80-11E1-9705-E1D010BDE39D.
- 01GR44F28E3ERPTX6QS5G7D4J2 dateCreated "2023-01-31T14:42:31Z".
- 01GR44F28E3ERPTX6QS5G7D4J2 dateModified "2024-10-29T08:51:35Z".
- 01GR44F28E3ERPTX6QS5G7D4J2 name "A lipid nanoparticle platform for RNA delivery with cationic amphiphilic drugs : merging the best of both worlds".
- 01GR44F28E3ERPTX6QS5G7D4J2 pagination urn:uuid:15729a1a-fe0d-486b-b985-9d2a18050402.
- 01GR44F28E3ERPTX6QS5G7D4J2 publisher urn:uuid:18503a54-0f60-4dd1-8e29-7821d94dfa3e.
- 01GR44F28E3ERPTX6QS5G7D4J2 sameAs LU-01GR44F28E3ERPTX6QS5G7D4J2.
- 01GR44F28E3ERPTX6QS5G7D4J2 sourceOrganization urn:uuid:3ca2c54a-35ce-4f34-b9c1-d16349b9a2bf.
- 01GR44F28E3ERPTX6QS5G7D4J2 type D1.